A new proteomic analysis is shedding a fresh light on the cytokine networks fueling idiopathic pulmonary fibrosis (IPF), ...
The FDA approved the combination of pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) for neoadjuvant and ...
The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease ...
New data supporting the safety and efficacy of tapinarof cream 1% (Vtama; Organon) for pediatric patients with atopic ...
Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition ...
Genetic predisposition to rheumatoid arthritis increases the risk of interstitial lung disease by 15.5%, as shown by Mendelian randomization analysis. The study used 52 single nucleotide polymorphisms ...
CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...
Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health ...
Panelists discuss how reinstating LDL-C targets in quality programs could improve outcomes and accountability. Stay ahead of ...
The FDA today approved selumetinib (Koselugo; Alexion, AstraZeneca Rare Disease) for the treatment of adults with ...
Adam Brufsky, MD, PhD, addresses how the COVID-19 pandemic affected breast cancer screening rates across Pittsburgh.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback